Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly's Phase 3 study highlights the effectiveness of Orforglipron in lowering blood sugar and promoting weight loss, ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...